# CTX112

Source: https://onco.cc/drugs/ctx112/  
OnCo record `ctx112` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CTX112 is an experimental CAR-T cell therapy from CRISPR Therapeutics in phase 2 trials for hodgkin lymphoma, chronic lymphocytic leukaemia and follicular lymphoma, aimed at CD19.

## Summary

CTX112 is a CAR-T cell therapy developed by CRISPR Therapeutics. Its target is CD19 (the sponsor names CD19). The sponsor states: An allogeneic CD19-directed CAR T-cell immunotherapy made from donor T cells genetically modified ex vivo using CRISPR-Cas9 gene editing (single guide RNA and Cas9 nuclease) to attack CD19-expressing B-cell malignancies. ClinicalTrials.gov describes the intervention as: CTX112 (CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in hodgkin lymphoma, chronic lymphocytic leukaemia, follicular lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma. The largest, NCT05643742, plans to enrol 120 participants with primary completion expected 2030-01. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: CAR-T cell therapy
- Mechanism: An allogeneic CD19-directed CAR T-cell immunotherapy made from donor T cells genetically modified ex vivo using CRISPR-Cas9 gene editing (single guide RNA and Cas9 nuclease) to attack CD19-expressing B-cell malignancies.

## Sources

- ClinicalTrials.gov: trials of CTX112: https://clinicaltrials.gov/search?intr=CTX112

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/)
- targets: [CD19](https://onco.cc/targets/cd19/)
- companies: [CRISPR Therapeutics](https://onco.cc/companies/crispr-therapeutics/)
- trials: [A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies](https://onco.cc/trials/nct05643742/)

---
JSON: https://onco.cc/api/v1/entities/ctx112.json